Insilico Medicine Names ISM6200 as a Promising Best-in-Class Selective NR3C1 Inhibitor for Ovarian Cancer, Cushing’s Syndrome, Obesity Linked to Hypercortisolism, and Glaucoma
In a groundbreaking stride forward in the realm of therapeutic innovation, Insilico Medicine, a clinical-stage company harnessing the power of ...
